Lassa virus antibody cocktail could be the first step in developing a vaccine
A research team from La Jolla Institute for Immunology in California, USA, have identifed a trio of antibodies that could be used to neutralize the Lassa virus
Researchers from La Jolla Institute for Immunology (LJI; CA, USA) have shown how a concoction of antibodies could be used to develop a vaccine for Lassa virus.
Lassa virus, a virus endemic to West Africa, gives rise to Lassa fever, which causes flu-like symptoms and affects around 300,000 people each year. The fever can lead to more severe symptoms and be fatal; pregnant women are particularly vulnerable with 90% of infections leading to death.
The Lassa virus has been under investigation by the Saphire lab at LJI for several years, studying images of the Lassa virus glycoprotein so that they can identify weaknesses – epitopes – that could be taken advantage of in finding a treatment option.
Recently, the researchers were able to isolate three rare antibodies from the blood of survivors of Lassa virus infection, with the hope that therapeutics based on these antibodies could be developed.
Initially, it was thought that antibodies would not be effective in protecting against Lassa virus, but by studying the structural map of the Lassa virus glycoprotein and using a combination of the three neutralising antibodies, the team were able to develop a ‘cocktail’ for testing.
This cocktail – named Arevirumab-3 – was tested in non-human primates, including those with an advanced form of the infection, and was proved to be 100% effective in treating the disease.
The next step was to test the cocktail in humans, where the team ran into a roadblock as the US FDA requires the mechanism of action to be clear before approving the launch of clinical trials.
The team were able to produce a glycoprotein that was an exact copy of the natural protein found on the Lassa virus, and this could be recognised by the three antibodies that made up the cocktail of Arevirumab-3. They then used cryo-electron microscopy single-particle analysis to produce high-resolution structural images of all of the elements, along with functional assays to show exactly how each of the antibodies bind to the glycoprotein.
“Lassa has another trick. It shields itself using a thick coat of human carbohydrate molecules—like a wolf in sheep’s clothing,” explained Erica Ollmann Saphire, lead researcher from LJI, “Haoyang’s [Haoyang Li, Instructor in the Saphire Lab, LJI] structures clearly show how these potent, protective antibodies breach or even utilize the carbohydrates to target and neutralise the virus.”
The stages of research have been published throughout the past year.
Saphire stated: “This body of work now offers the first-ever full-epitope map, revealing every vulnerable target of the Lassa glycoprotein.”
From this, the team will be able to move Arevirumab-3 into clinical trial phases and hopefully develop a vaccine to protect against Lassa virus in the near future.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance